Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EL625 with FCR in Persistent CLL/SLL
NCT00636155Phase 2Terminated
- Start
- Feb 2008
- Primary completion
- Aug 2011
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of cenersen sodium in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started Feb 2008; status: terminated.
02
Drugs
cenersen sodium
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00636155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636155.